Last reviewed · How we verify
NCT04774081: CGM-PEPTIDE
Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study
trial testing 24h Continuous glucose monitoring and urinary C-peptide collection in Insulin Sensitivity in 13 participants. Completed in 21 February 2022.
21 February 2022
Quick facts
| Lead sponsor | Pennington Biomedical Research Center |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 13 |
| Start date | 8 February 2021 |
| Primary completion | 21 February 2022 |
| Estimated completion | 21 February 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 24h Continuous glucose monitoring and urinary C-peptide collection
Conditions studied
- Insulin Sensitivity — all drugs for Insulin Sensitivity →
Sponsor
Pennington Biomedical Research Center — full company profile →
Who can join
Adults 18 to 65, any sex, with Insulin Sensitivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Amphibians as a source of bioactive antioxidant peptides: Emerging insights and therapeutic potential.
Zhu YY, Zhao LM, Jia XY, Liao GJ, et al · · 2025 · PMID 41017405 · DOI 10.24272/j.issn.2095-8137.2025.127
Verify or expand the search:
- PubMed search for NCT04774081
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Insulin Sensitivity
Currently open trials in the same condition.
- NCT07247734 — The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation · Phase 2 · recruiting
- NCT06939959 — Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease. · Phase 4 · recruiting
- NCT06649981 — Aging Resilience Through Microbiota Optimization and Regulation · Phase 1 · active not recruiting
- NCT06487832 — Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness · NA · recruiting
- NCT06878781 — Postprandial Metabolome and Metabolic Flexibility · NA · recruiting
Other Pennington Biomedical Research Center trials
Trials by the same sponsor.
- NCT07530718 — Body Composition Outcomes in MS Patients · not yet recruiting
- NCT07095972 — Continuous Glucose Monitoring in Metabolic Surgery · NA · not yet recruiting
- NCT07139821 — Dietary Iron Requirements · recruiting
- NCT07318064 — Ultra-processed Food Consumption and Health Pilot Study · NA · not yet recruiting
- NCT07305753 — CanCan Body Composition Study · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04774081 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pennington Biomedical Research Center
- Last refreshed: 14 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04774081.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing